文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症干细胞标志物CD24、CD44和CD133在胰腺导管腺癌和慢性胰腺炎中的表达及临床意义

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.

作者信息

Durko L, Wlodarski W, Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M, Hogendorf P, Strzelczyk J, Malecka-Panas E

机构信息

Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland.

Department of Pathomorphology, Medical University of Lodz, Lodz, Poland.

出版信息

Dis Markers. 2017;2017:3276806. doi: 10.1155/2017/3276806. Epub 2017 Jun 4.

DOI:10.1155/2017/3276806
PMID:28659655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5474271/
Abstract

Cancer stem cells (CSC) play an important role in pancreatic carcinogenesis and prognosis. The study aimed at examining the expression of CD24, CD44, and CD133 in human PDAC and CP in order to evaluate its clinicopathological correlations and the clinical significance. Surgical specimens from 23 patients with PDAC and 15 patients with chronic pancreatitis after pancreatic resection were stained with CD24, CD44, and CD133 antibodies. The intensity of staining was scored from 0 (negative) to 3 (strongly positive). . Mean CD24 staining score in PDAC was 1.38 ± 0.76 and was significantly higher than that in CP: 0.70 ± 0.53 ( < 0.01); CD44 score in PDAC was 2.23 ± 0.42 and was significantly higher than that in CP: 1.87 ± 0.55 ( < 0.05); CD133 score 0.93 ± 0.58 was not different from CP: 0.71 ± 0.43 ( > 0.05). CD44 immunoreactivity was significantly higher ( < 0.05) in pT1 and pT2 patients together as regards pT3: 2.45 ± 0.37 versus 2.06 ± 0.38 as well as in N0 patients compared to N1 patients: 2.5 ± 0.38 versus 2.04 ± 0.34. . CD24 and CD44 are upregulated in human pancreatic cancer compared to chronic pancreatitis. CD44 immunoreactivity decreases with the tumor advancement and may represent the negative PDAC prognostic factor. Each CSC marker was differently related to PDAC advancement. CD133 may lack clinical significance in PDAC.

摘要

癌症干细胞（CSC）在胰腺癌的发生和预后中起着重要作用。本研究旨在检测CD24、CD44和CD133在人胰腺导管腺癌（PDAC）和慢性胰腺炎（CP）中的表达，以评估其与临床病理的相关性及临床意义。对23例PDAC患者和15例胰腺切除术后慢性胰腺炎患者的手术标本用CD24、CD44和CD133抗体进行染色。染色强度从0（阴性）到3（强阳性）进行评分。PDAC中CD24染色平均评分为1.38±0.76，显著高于CP中的评分：0.70±0.53（P<0.01）；PDAC中CD44评分2.23±0.42，显著高于CP中的评分：1.87±0.55（P<0.05）；CD133评分0.93±0.58与CP中的评分0.71±0.43无差异（P>0.05）。在pT1和pT2患者中，CD44免疫反应性显著高于pT3患者：2.45±0.37对2.06±0.38，在N0患者中高于N1患者：2.5±0.38对2.04±0.34。与慢性胰腺炎相比，CD24和CD44在人胰腺癌中上调。CD44免疫反应性随肿瘤进展而降低，可能是PDAC的负性预后因素。每个CSC标志物与PDAC进展的关系不同。CD133在PDAC中可能缺乏临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/9f3a7a63a887/DM2017-3276806.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/9ac676a8cdd9/DM2017-3276806.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/2656ad520418/DM2017-3276806.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/75de417af7e1/DM2017-3276806.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/af5134a6cb57/DM2017-3276806.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/64ac8b038fbe/DM2017-3276806.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/db4e2d8c9c27/DM2017-3276806.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/e3ac10a1a4c8/DM2017-3276806.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/3890255db0c7/DM2017-3276806.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/082f9a86309a/DM2017-3276806.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/a99c7f9269a3/DM2017-3276806.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/e5fed0d7604d/DM2017-3276806.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/9f3a7a63a887/DM2017-3276806.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/9ac676a8cdd9/DM2017-3276806.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/2656ad520418/DM2017-3276806.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/75de417af7e1/DM2017-3276806.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/af5134a6cb57/DM2017-3276806.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/64ac8b038fbe/DM2017-3276806.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/db4e2d8c9c27/DM2017-3276806.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/e3ac10a1a4c8/DM2017-3276806.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/3890255db0c7/DM2017-3276806.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/082f9a86309a/DM2017-3276806.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/a99c7f9269a3/DM2017-3276806.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/e5fed0d7604d/DM2017-3276806.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/5474271/9f3a7a63a887/DM2017-3276806.012.jpg

相似文献

[1]
Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.

Dis Markers. 2017

[2]
Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.

Int J Oncol. 2012-7-23

[3]
Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.

Pathol Res Pract. 2017-8

[4]
Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.

Cancer. 2014-9-1

[5]
Are CD44/CD24 cells the assumed cancer stem cells in breast cancer?

Exp Oncol. 2017-9

[6]
The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases.

Anticancer Res. 2018-1

[7]
Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.

World J Gastroenterol. 2009-5-14

[8]
Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.

Sci Rep. 2017-10-23

[9]
Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.

Clin Cancer Res. 2017-6-1

[10]
Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.

PLoS One. 2016-7-14

引用本文的文献

[1]
A Novel Anti-CD44 Variant 9 Monoclonal Antibody CMab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers.

Curr Issues Mol Biol. 2023-4-20

[2]
The dual role of p63 in cancer.

Front Oncol. 2023-4-27

[3]
Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC Cells.

Cancers (Basel). 2023-2-7

[4]
Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.

J Cancer Res Clin Oncol. 2023-6

[5]
Current Pathology Model of Pancreatic Cancer.

Cancers (Basel). 2022-5-7

[6]
Effects of tRNA-derived fragments and microRNAs regulatory network on pancreatic acinar intracellular trypsinogen activation.

Bioengineered. 2022-2

[7]
CD44: A Multifunctional Mediator of Cancer Progression.

Biomolecules. 2021-12-9

[8]
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance.

Cancer Metastasis Rev. 2021-9

[9]
Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence.

Cancers (Basel). 2021-2-20

[10]
Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours.

Oncol Lett. 2020-12

本文引用的文献

[1]
Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.

Oncol Lett. 2016-10

[2]
Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma.

World J Gastrointest Oncol. 2016-8-15

[3]
Modifiable and non-modifiable risk factors for pancreatic cancer: A review.

Cancer Lett. 2016-7-25

[4]
Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.

PLoS One. 2016-7-14

[5]
CD90 and CD24 Co-Expression Is Associated with Pancreatic Intraepithelial Neoplasias.

PLoS One. 2016-6-22

[6]
Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.

Int J Clin Exp Pathol. 2015-10-1

[7]
Microvascular density and endothelial area correlate with Ki-67 proliferative index in surgically-treated pancreatic ductal adenocarcinoma patients.

Oncol Lett. 2015-8

[8]
Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer.

Dig Dis Sci. 2016-4

[9]
Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.

Cancer Res. 2015-11-1

[10]
Expression of CD44 in pancreatic cancer and its significance.

Int J Clin Exp Pathol. 2015-6-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索